Countries may or may not choose to give their share doses to Covax, but regardless, redistribution needs to be driven by need.
L’expertise universitaire, l’exigence journalistique
Articles sur Coronavirus vaccines
Affichage de 61 à 80 de 125 articles
Michelle Grattan discusses the political week that was with Professor Paddy Nixon
Both vaccines appear to reduce the risk of developing COVID-19, and so could be approved later this year.
New guidelines take a broad definition of who can apply for a religious exemption to vaccinations. A lot will hinge on what constitutes ‘undue hardship’ to the employer.
Selfishness was also a problem when the world was developing vaccines for swine flu and bird flu.
On the face of it, it seems like a good idea.
Results from individual studies are very precise, and not always the best grounds for making policy decisions.
Lower than expected deliveries of AstraZeneca vaccines are exposing the bloc’s slow rollout.
Production limits the rate at which vaccines can be rolled out, and is at the heart of the current disagreements between the UK and EU.
Getting a vaccine is proving difficult for many older people now, but the mad rush for the vaccine won’t last long. Many people don’t want to get one at all, and that will impede herd immunity.
Israel is vaccinating its population at an impressive rate and sharing the data with the world. But at what price?
We’ve gone from a novel virus to several COVID-19 vaccines in less than a year. Here’s what we’ve learned from earlier vaccines to allow this to happen.
Vaccines that use harmless viruses as a delivery mechanism are vulnerable to being attacked by our immune system – but experimenting with how they are given could get around this.
History tells us that mass vaccination campaigns are usually messy, while elsewhere, lower-income countries are turning to China, Russia and India for vaccines.
Your chance to ask a panel of experts about the coronavirus variants at 12.30pm GMT on Wednesday January 27.
History tells us that delays, administrative hurdles, messiness and complexity are the norm.
All sorts of transactions are “two-way value exchanges” in which it isn’t clear in which direction the money should flow. The proposed media bargaining code is one of them.
As vaccination begins to take effect, what we’ll be able to do will change – but the transformation will be slow.
As the coronavirus rages, a vaccine finally is available for certain groups of people and will soon be ready for other groups. But there are plenty of questions. A doctor answers five here.
The UK government needs to show solidarity with the public.
Les contributeurs les plus fréquents
-
Professorial Fellow, University of Canberra
-
Professor of Medicine, University of East Anglia
-
FAPESP-Postdoctoral Researcher at the Laboratory of Structural Biology and Zoochemistry, IB/RC (UNESP), University of São Paulo State
-
Professor of Economics, University of Birmingham
-
Associate Professor of Biology, Rochester Institute of Technology
-
Senior Lecturer in Biochemistry and Cell Biology, University College Cork
-
Associate professor, UNSW Sydney
-
Senior Research Fellow in Global Health, University of Southampton
-
Dean of the National School of Tropical Medicine and Professor of Pediatrics and Molecular Virology & Microbiology, Baylor College of Medicine
-
Associate Professor of Marketing, University of Technology Sydney
-
Professor, Languages, Literatures and Cultures, Queen's University, Ontario
-
Principal Lecturer, Microbiology and Biomedical Science Practice, Fellow of the Institute of Biomedical Science, University of Brighton
-
Assistant Professor of Political Science, Oklahoma State University
-
Early Career Research Leader, Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University
-
Professor of Economics, University of Maryland
